Videos

In a recent interview, Josh Gurewitz and Ajit Shankaranarayanan, PhD, discussed the utility of AI-powered software, including the recently FDA-cleared SubtleHD(PET), for bolstering efficiency and quality with PET imaging.

A randomized controlled trial found that combining Disney characters with soothing ambient elements for pediatric MRI reduced anxiety levels by 43 percent in children under 10 years of age.

The SubtleHD(PET) software reportedly facilitates enhanced image quality, provides improved SUVmax quantitative accuracy and compatibility with all FDA-approved radiotracers.

In recent interviews, Emanuel Kanal, MD, and Tobias Gilk, MRSO, MRSE, discuss new multicenter research examining pediatric MRI safety as well as key challenges and preventive measures in this patient population.

Catch up on the top radiology content of the past week.

In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses current and potential pre-procedure, intra-procedure and post-procedure applications of AI for interventional radiology.

Prostate AI reportedly enhances lesion detection, reduces segmentation variability between radiologists and improves workflow efficiencies in biopsy-recommended cases.

The ACIST Pro Diagnostic System, a variable-rate contrast management platform, reportedly offers real-time contrast tracking for image-guided interventional cardiology procedures and reduces set-up time by one-third in comparison to the ACIST CVI device.

Catch up on the top radiology content of the past week.

In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, discusses a new study of breast arterial calcification on mammography and practical clinical implications for breast radiologists.

The updated Break Wave lithotripsy device for kidney stone treatment reportedly has ultrasound therapy probes with a 31 percent smaller footprint.

In a recent interview, Shadpour Demehri, MD, discussed new research findings suggesting a correlation between emphysema-like changes on CT and reduced bone mineral density in patients without chronic obstructive pulmonary disease (COPD).

Four versions of the Artis vision platform and floor configurations of the Artis icono.explore and Artis genio systems feature the Optiq AI imaging chain, which reportedly facilitates real-time analysis and data optimization.

In a recent interview with Diagnostic Imaging, Leslie Lamb, MD, MSc, discussed findings from new mammography research that showed an 89.3 percent sensitivity for detecting invasive lobular carcinoma (ILC) with adjunctive AI.

Catch up on the top radiology content of the past week.

In a recent interview with Diagnostic Imaging, Soroush Adam Ramin, MD, discussed the enhanced 3D visualization and prognostic capability of Unfold AI, an MRI-based software platform that was recently added to Medicare Physician Fee Schedules for the West Coast and Mountain West regions.

PSMA PET improves staging in advanced and recurrent prostate cancer, guiding shared decisions with expert interpretation and paving the way for theranostics.

New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA.

In a recent interview with Diagnostic Imaging, Wendie Berg, MD, PhD, shared her perspective on various aspects of the controversial breast cancer screening guidance issued by the American College of Physicians (ACP), including the use of supplemental imaging in women with dense breasts.

In a recent interview with Diagnostic Imaging, Manisha Bahl, MD, MPH, SBI, offers pertinent insights on the controversial breast cancer screening guidance recently issued by the American College of Physicians (ACP).

Catch up on the top radiology content of the past week.

Real-world PSMA PET use in prostate cancer reveals variable readings and PSA thresholds, prompting selective scans and ongoing trials with FDG PET.

Learn how evolving PSMA PET reporting standards reshape prostate cancer staging and influence therapy choices, from SBRT to triplet regimens.

Learn who reads PSMA PET scans and why a multidisciplinary team translates results into clearer prostate cancer treatment and imaging decisions.

Learn how next‑gen prostate cancer imaging outperforms CT and bone scans, revealing micrometastases and guiding team-based treatment decisions.

In a recent interview, Stamatia Destounis, MD, offered her perspective about the recent American College of Physicians (ACP) guidance on breast cancer screening and concerns over recommendations in women with dense breasts and biennial versus annual mammography screening.

Learn how PSMA PET sharpens staging, guides Pluvicto dosing, and avoids false-positive traps—changing treatment for advanced prostate cancer.

Clinicians weigh PSMA PET’s strengths, limits, and tracer differences, plus when to scan after recurrence to guide salvage prostate cancer therapy.

Learn how FDA-approved PSMA PET tracers differ in prostate cancer staging and recurrence, including urinary uptake nuances that may affect post-prostatectomy detection.

PSMA PET reshapes advanced prostate cancer care, guiding Pluvicto use and tracking response with emerging PCWG4 criteria.